New Mexico Educational Retirement Board Sells 2,800 Shares of AbbVie Inc. $ABBV

New Mexico Educational Retirement Board trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% in the third quarter, Holdings Channel.com reports. The fund owned 79,755 shares of the company’s stock after selling 2,800 shares during the quarter. AbbVie makes up approximately 0.6% of New Mexico Educational Retirement Board’s investment portfolio, making the stock its 22nd biggest position. New Mexico Educational Retirement Board’s holdings in AbbVie were worth $18,467,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Ellenbecker Investment Group increased its position in AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA lifted its position in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares during the period. Matthew Goff Investment Advisor LLC boosted its stake in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after purchasing an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC boosted its stake in shares of AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after purchasing an additional 45 shares during the last quarter. Finally, Willner & Heller LLC increased its position in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of analyst reports. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Barclays assumed coverage on AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.25% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $206.32 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The business’s 50 day simple moving average is $223.41 and its two-hundred day simple moving average is $224.71. The firm has a market cap of $364.80 billion, a P/E ratio of 87.42, a PEG ratio of 0.72 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) released new global consumer research and updated educational programs that could support its aesthetics franchise and long‑term revenue diversification. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Independent valuation and market‑commentary pieces highlight a recent share‑price pullback and renewed debate over AbbVie’s near‑term multiple; these analyses may lead to more analyst revisions but are not a direct operational hit. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: FDA approved J&J’s Icotyde, the first oral IL‑23 inhibitor, creating direct competition for Skyrizi; analysts and articles warn Icotyde could capture significant market share because of oral dosing convenience, pressuring AbbVie’s key growth driver. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: multiple outlets report a ~5% intraday drop and continued underperformance vs. peers as investors price in Icotyde competition and reassess AbbVie’s growth outlook. Elevated volume suggests defensive positioning. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: Breckenridge launched a generic version of Savella (milnacipran), which introduces additional generic competition in a product AbbVie previously marketed—incremental revenue headwind for that niche pain product. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.